Health Care • Biotechnology: Pharmaceutical Preparations
$5.70 ▼ -1.94
(-25.46%)
MKT CAP: $595.5M • VOL: 7.02M
52W L $6 52W H $13
CRMD // SEC EDGAR XBRL STANDARDIZED FINANCIAL STATEMENTS (FA <GO>)
| LINE ITEM (USD / %) | FY 2025
FILED 2025-12-31 | FY 2024
FILED 2024-12-31 | FY 2023
FILED 2023-12-31 |
|---|---|---|---|
| Revenue (Total Sales) | $311.7M | $43.5M | $0 |
| YoY Revenue Growth % | +617.0% | — | — |
| Gross Profit | $275.7M | $40.3M | — |
| Gross Margin % | 88.5% | 92.7% | — |
| Research & Development (R&D) | — | — | — |
| Operating Income (EBIT) | $150.1M | -$22.4M | -$49.0M |
| Operating Margin % | 48.2% | -51.4% | — |
| Net Income (GAAP) | $163.1M | -$17.9M | -$46.3M |
| EBITDA (Normalized) | $151.9M | -$22.3M | — |
| Diluted EPS ($/sh) | — | — | — |
| Operating Cash Flow (OCF) | $175.0M | -$50.6M | -$38.4M |
| Capital Expenditures (CapEx) | $2.3M | $116.0K | — |
| Free Cash Flow (FCF) | $172.8M | -$50.7M | -$38.4M |
| FCF Margin % | 55.4% | -80.0% | — |
| Return on Invested Capital (ROIC %) | 45.5% | -40.1% | — |
| Cash & Short-Term Equivalents | $144.8M | $40.7M | — |
| Total Debt (Short + Long Term) | — | — | — |
| Total Stockholders' Equity | $405.3M | $84.7M | — |
NO QUARTERLY 10-Q XBRL STATEMENTS AVAILABLE IN CURRENT CACHE FOR CRMD.